{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:17:50Z","timestamp":1773515870439,"version":"3.50.1"},"reference-count":18,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Hereditary type 1 tyrosinemia (HT1) is a rare inherited autosomal recessive disorder of tyrosine metabolism, characterized by progressive liver damage, dysfunction of kidney tubules, and neurological crises. In the course of this disease, due to the deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), toxic intermediate metabolites of tyrosine breakdown, such as fumarylacetoacetate (FAA), succinylacetoacetate (SAA), and succinylacetone (SA), accumulate in liver and kidney cells, causing cellular damage. Because of this, an increased SA concentration in the blood or urine is pathognomonic of HT1. In the year 2000, HT1 was diagnosed in Lithuania for the first time, and this was the first time when a specific treatment for HT1 was administered in the country. Over two decades, four cases of this disease have been diagnosed in Lithuania. In the first of these patients, the disease was diagnosed in infancy, manifesting as liver damage with liver failure. Treatment with nitisinone was initiated, which continues to be administered, maintaining normal liver function. Liver transplantation was performed on two subsequent patients due to complications of HT1. It is crucial to diagnose HT1 as early as possible in order to reduce or completely eliminate complications related to the disease, including progressive liver failure and kidney dysfunction, among others. This can only be achieved by conducting a universal newborn screening for tyrosinemia and by starting treatment with nitisinone (NTBC) before the age of 1 month in all cases of HT1. However, in those countries where this screening is not being carried out, physicians must be aware of and consider this highly rare disorder. They should be vigilant, paying attention to even minimal changes in a few specific laboratory test results\u2014such as unexplained anemia alongside neutropenia and thrombocytopenia\u2014and should conduct more detailed examinations to determine the causes of these changes. In this article, we present the latest clinical case of HT1 in Lithuania, diagnosed at the Children\u2019s Diseases\u2019 Clinic of the Lithuanian University of Health Sciences (LUHS) Hospital Kaunas Clinics. The case manifested as life-threatening acute liver failure in early childhood. This article explores and discusses the peculiarities of diagnosing this condition in the absence of universal newborn screening for tyrosinemia in the country, as well as the course, treatment, and ongoing monitoring of patients with this disorder.<\/jats:p>","DOI":"10.3390\/medicina60010135","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:21:41Z","timestamp":1704943301000},"page":"135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood"],"prefix":"10.3390","volume":"60","author":[{"given":"R\u016bta","family":"Rokait\u0117","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Medical Academy, Lithuanian University of Health Sciences, LT 44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u0117","family":"\u010cibirkait\u0117","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Academy, Lithuanian University of Health Sciences, LT 44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vykinta","family":"Zeleckyt\u0117","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Academy, Lithuanian University of Health Sciences, LT 44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabija","family":"Lazdinyt\u0117","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, LT 44307 Kaunas, Lithuania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"D\u017eenkaitis","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Health and Agricultural Sciences, University College Dublin, Belfield, D04 V1W8 Dublin, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"ref_1","first-page":"514","article-title":"Hereditary tyrosinemia type I: Newborn screening, diagnosis and treatment","volume":"50","author":"Tang","year":"2021","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Bao"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ped.12550","article-title":"Diagnosis and treatment of hereditary tyrosinemia in Japan","volume":"57","author":"Nakamura","year":"2015","journal-title":"Pediatr. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type I: A US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet. Med."},{"key":"ref_4","first-page":"525","article-title":"Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15","volume":"48","author":"Phaneuf","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/8904_2014_363","article-title":"Geographical and ethnic distribution of mutations of the fumarylacetoacetate hydrolase gene in hereditary tyrosinemia type 1","volume":"19","author":"Angileri","year":"2015","journal-title":"JIMD Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1399-0004.2005.00497.x","article-title":"Population history and its impact on medical genetics in Quebec","volume":"68","author":"Laberge","year":"2005","journal-title":"Clin. Genet."},{"key":"ref_7","unstructured":"Scriver, C.R., Beaudet, A.L., Sly, W.S., and Valle, D. (2001). The Metabolic and Molecular Bases of Inherited Disease, McGraw Hill."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/00365513.2012.676210","article-title":"Hereditary tyrosinaemia type I in Norway: Incidence and three novel small deletions in the fumarylacetoacetase gene","volume":"72","author":"Bliksrud","year":"2012","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/(SICI)1097-0223(199710)17:10<964::AID-PD164>3.0.CO;2-6","article-title":"Mutation analysis for prenatal diagnosis of hereditary tyrosinaemia type 1","volume":"17","author":"Mustonen","year":"1997","journal-title":"Prenat. Diagn."},{"key":"ref_10","unstructured":"Adam, M.P., Feldman, J., and Mirzaa, G.M. (2024, January 07). Tyrosinemia Type I, GeneReviews\u00ae [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1515\/."},{"key":"ref_11","first-page":"280","article-title":"Type 1 tyrosinemia in Finland: A nationwide study","volume":"15","author":"Hiltunen","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-021-01879-1","article-title":"Treatment adherence in tyrosinemia type 1 patients","volume":"16","author":"Andrade","year":"2021","journal-title":"Orphanet, J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1542\/peds.2014-1913","article-title":"Hepatocellular carcinoma in tyrosinemia type 1 without clear increase of AFP","volume":"135","author":"Gouw","year":"2015","journal-title":"Pediatrics"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jceh.2020.07.002","article-title":"Outcome of Tyrosinemia Type 1 in Indian Children","volume":"11","author":"Mirani","year":"2021","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_15","unstructured":"Elder, A.J., and Ali, S. (2023). StatPearls, StatPearls Publishing LLC."},{"key":"ref_16","unstructured":"Adnan, M., and Puranik, S. (2023). StatPearls, StatPearls Publishing LLC."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","article-title":"Recommendations for the management of tyrosinaemia type 1","volume":"8","author":"Leonard","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-014-0107-7","article-title":"Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice","volume":"9","author":"Mayorandan","year":"2014","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:44:23Z","timestamp":1760103863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010135"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010135","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]}}}